Function lab testing detects early signals associated with more than 50 types of cancer.
"Function gives you access to more than 160 advanced lab tests spanning hormones, heart health, kidney function, and even detects early signals linked to more than 50 types of cancer." (said at 0:53:44)
Multi-cancer early detection (MCED) blood testing offered through health platforms (such as the Galleri test by GRAIL) evaluates cell-free DNA (cfDNA) methylation patterns to screen for cancer signals. Clinical validation in a large independent cohort of 4,077 participants (CCGA study substudy 3) confirmed that the test detected cancer signals across more than 50 distinct cancer types with 99.5% specificity, though sensitivity was considerably higher in late stages (77.0% in stage III, 90.1% in stage IV) compared to early stages (16.8% in stage I, 40.4% in stage II).
- supports: Clinical validation of a targeted methylation-based multi-cancer early detection test usin… (Annals of oncology : official journal of the European Society for Medical Oncology 2021)
"Stage I-III sensitivity was 67.6% (64.4% to 70.6%) in 12 pre-specified cancers that account for approximately two-thirds of annual USA cancer deaths and was 40.7% (38.7% to 42.9%) in all cancers. Cancer signals were detected across >50 cancer types." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Multi-cancer early detection tests for general population screening: a systematic literatu… (Health technology assessment (Winchester, England) 2025)
"Individual tests claimed to detect from 3 to over 50 different types of cancer. Diagnostic accuracy of currently available multi-cancer early detection tests varied substantially: Galleri ® (GRAIL, Menlo Park, CA, USA) sensitivity 20.8-66.3%, specificity 98.4-99.5% (three studies)" (abstract, results)
pubmedfull study (doi)